WADA raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
=== Pharmacokinetics === When administered together as dextromethorphan/bupropion, the elimination half-life of dextromethorphan is 22 hours and the elimination half-life of bupropion is 15 hours. The elimination half-lives of bupropion active metabolites are 35 hours for hydroxybupropion, 44 hours for erythrohydrobupropion, and 33 hours for threohydrobupropion. Bupropion inhibits the metabolism of dextromethorphan by inhibiting the enzyme CYP2D6, the major enzyme responsible for the metabolism of dextromethorphan. This in turn improves the bioavailability of dextromethorphan, prolongs its half-life, prevents its metabolism into dextrorphan, and increases the ratio of dextromethorphan to dextrorphan in the body.
28 September A breakthrough in treating Alzheimer's disease is reported by pharmaceutical companies Eisai and Biogen, using a drug called lecanemab, which is designed to remove beta-amyloid proteins from the brain. A study indicates cancer risk from chronic circadian disruption is caused via body-temperature-related heat shock factor 1. Researchers report the discovery of hemoglycin, the first space polymer of amino acids found in meteorites. 29 September In two studies, scientists report a novel way of cancer screening – detecting tumor-associated mycobiomes. It could be used in synergy with other biomarkers such as of bacterial microbiomes. A study estimates the disproportionality of drivers of climate change by wealth and concludes that to total emissions, investments of the global top 1% are far more important than their consumption and that the pollution gap is larger within countries than between countries. A study adds to the accumulating research showing that oil and gas industry methane emissions are much larger than thought. 30 September The discovery of "super neurons" in the entorhinal cortex of people over age 80 who show exceptional episodic memory is reported. Scientists caution about potential future spillover of SHFV.
== U == Ultradian rhythm A recurrent biological cycle that occurs more than once in 24 hours, such as stages of sleep. In neuroscience, it refers to shorter rhythms regulating hormonal release, arousal, or sleep cycles. Unconditioned response In classical conditioning, an automatic, reflexive response to an unconditioned stimulus (e.g., salivation to food). Studied in behavioral neuroscience. Unconsciousness A state in which an individual is not aware of themselves or their surroundings. Can result from head injury, anesthesia, or metabolic dysfunction. Uncus A structure on the medial surface of the temporal lobe, part of the parahippocampal gyrus. It is involved in olfaction and is adjacent to the amygdala. Undershoot The hyperpolarizing phase following an action potential where membrane potential temporarily becomes more negative than resting potential. Unilateral neglect A neuropsychological condition following damage (typically to the right parietal lobe) in which patients ignore stimuli on one side of space. Unipolar depression A mood disorder characterized by persistent low mood, lack of energy, and anhedonia, without manic episodes. Associated with altered activity in the prefrontal cortex and limbic structures. Unipolar neuron A type of neuron with a single process extending from the cell body. Common in invertebrates and found in human sensory neurons. Upper motor neuron A neuron originating in the cerebral cortex or brainstem that transmits motor signals to lower motor neurons. Damage leads to spasticity, hyperreflexia, and weakness.
=== Do–Dy === Martha Doan (1872–1960), American chemist who studied thallium compounds William von Eggers Doering (1917–2011), American chemist known for the total synthesis of quinine Edward Doisy (1893–1986), American biochemist, winner of the 1943 Nobel Prize in Physiology or Medicine Davorin Dolar (1921–2005), Slovenian physical chemist who studied polyelectrolyte solutions, and is regarded as a founder of modern physical chemistry teaching in Slovenia Vy Maria Dong (born 1976), American chemist who studies enantioselective catalysis and natural product synthesis David Adriaan van Dorp (1915–1995), Dutch chemist known for the first full synthesis of vitamin A Israel Dostrovsky (1918–2010), Russian (Ukraine)-born Israeli physical chemist known for separating oxygen isotopes in water Herbert Henry Dow (1866–1930), American industrial chemist, known for bromine extraction Cornelius Drebbel (1572–1633), Dutch inventor, alchemist and chemist who contributed to develop measurement and control systems, optics and chemistry Jean Baptiste Dumas (1800–1884), French chemist, best known for the determination of atomic and molecular masses weights by measuring vapor densities Helen Dyer (1895–1998), American biochemist and early cancer researcher known for studies of carcinogenesis mechanisms
Sources: en.wikipedia.org
== Organisms and discovery == Creatinase was first identified by Roche, Lacombe, & Girard in 1950 in Pseudomonas eisenbergii and P. ovalis. It is produced by other bacterial genera including Bacillus, Flavobacterium, Micrococcus, Alcaligenes, Clostridium, Arthrobacter, and Paracoccus, and is produced by other species of Pseudomonas as well. In P. putida, creatinase is coded for by the creA gene and enables growth on creatine as the sole nitrogen source. Expression of creA is regulated by CahR, an AraC/GAT-R regulator that activates gene expression in the presence of creatine. This gene has also been cloned into Escherichia coli.
== The document == The document was presented to the British Museum in 1924 by Walter Rothschild; today it is held in the British Library, which separated from the British Museum in 1973, as Additional Manuscripts number 41178. From October 1987 to May 1988 it was lent outside the UK for display in Israel's Knesset.
Due to the high sulfur content of the Athabasca Oil Sands, stockpiles of elemental sulfur from this process exist throughout Alberta, Canada. Another way of storing sulfur is as a binder for concrete, the resulting product having some desirable properties (see sulfur concrete). The world production of sulfur in 2011 amounted to 69 million tonnes (Mt), with more than 15 countries contributing more than 1 Mt each. Countries producing more than 5 Mt are China (9.6), the United States (8.8), Canada (7.1) and Russia (7.1). Production has been slowly increasing from 1900 to 2010; the price was unstable in the 1980s and around 2010.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.